Targeted protein degradation or TPD, is rapidly emerging as a treatment that utilizes small molecules to degrade proteins that cause diseases. TPD allows for the selective removal of disease-causing proteins, including proteasome-mediated degradation, lysosome-mediated degradation, and autophagy-mediated degradation. This approach has shown great promise in preclinical studies and is now being translated to treat numerous diseases, including neurodegenerative diseases, infectious diseases, and cancer. This review discusses the latest advances in TPD and its potential as a new chemical modality for immunotherapy, with a special focus on the innovative applications and cutting-edge research of PROTACs (Proteolysis TArgeting Chimeras) and their efficient translation from scientific discovery to technological achievements. Our review also addresses the significant obstacles and potential prospects in this domain, while also offering insights into the future of TPD for immunotherapeutic applications.
- MeSH
- chiméra pro cílenou proteolýzu MeSH
- imunoterapie * metody MeSH
- lidé MeSH
- nádory terapie farmakoterapie imunologie metabolismus MeSH
- proteasomový endopeptidasový komplex * metabolismus MeSH
- proteolýza * účinky léků MeSH
- ubikvitin * metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- chiméra pro cílenou proteolýzu MeSH
- proteasomový endopeptidasový komplex * MeSH
- ubikvitin * MeSH
